18-40 years old | Female
This vaccine (mRNA-1647) is designed to protect against cytomegalovirus (CMV) infection. This trial is for individuals who are both CMV seronegative (never had CMV) and CMV seropositive (had CMV in the past).
This vaccine (mRNA-1647) is designed to protect against cytomegalovirus (CMV) infection. This trial is for individuals who are both CMV seronegative (never had CMV) and CMV seropositive (had CMV in the past).
Up to 14 visits over ~30 months
Participants are paid for diary compliance and for time and travel associated with completion of study visits